Scleroderma (Systemic Sclerosis) – Landscape & Forecast – Disease Landscape & Forecast
Scleroderma, also known as systemic sclerosis (SSc), is a rare, progressive, and debilitating autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that manifests as Raynaud’s disease, skin thickening, and, often, painful digital ulcers. Mortality risks of pulmonary arterial hypertension (PAH), interstitial lung disease (ILD), and renal crisis are high in SSc patients. Boehringer Ingelheim’s Ofev (nintedanib) and Roche / Genentech’s Actemra / RoActemra (tocilizumab) are two of the more-recent therapies specifically targeting the SSc–ILD subpopulation. They have demonstrated the ability to slow the progressive loss of lung function. Other therapies are commonly prescribed off-label for overlapping symptoms. Although the SSc pipeline is large and diverse, most agents are in early development. Moreover, the development of SSc therapies has historically been associated with high failure rates, in part due to the heterogeneity of the patient population and the commensurate challenges with trial design.
Questions answered
- How large is the diagnosed SSc population in the United States and EU5, and how will it change over the next 10 years?
- What is the current treatment landscape in SSc?
- What is the impact of newer-to-market therapies, and how will they change the treatment landscape over the next 10 years?
- What do key opinion leaders view as the greatest unmet medical needs in the management of SSc?
- What is the commercial potential of key emerging therapies? How will they fit into the SSc treatment landscape?
Content highlights
- Geographies: United States and EU5.
- Primary research: Six country-specific interviews with thought-leading SSc specialists supported by survey data collected for this study.
- Epidemiology: Diagnosed prevalence of SSc by country, disease severity, and drug-treatment rates.
- Forecast: Drug-level sales and patient share of key SSc therapies through 2032.
- Emerging therapies: Phase 3: 1 drug; Phase 1 / 2: 9 drugs.
Product description
Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Niche & Rare Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Scleroderma (Systemic Sclerosis) - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Commercial Outlook
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Key findings
- Diagnosis
- Treatment goals
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for scleroderma (systemic sclerosis)
- Current treatments used for scleroderma (systemic sclerosis)
- Market events impacting the use of key current therapies for systemic sclerosis
- Use of key drug classes for the manifestations of systemic sclerosis
- Angiotensin-converting enzyme inhibitors
- Autologous hematopoietic stem-cell transplantation
- B-cell modulators
- Calcium-channel blockers
- Endothelin receptor antagonists
- Guanylate cyclase stimulants
- Interleukin-6 inhibitors
- Immunosuppressants
- Phosphodiesterase-5 inhibitors
- Prostacyclin analogues
- Tyrosine kinase inhibitors
- Medical practice
- Key findings
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Access & Reimbursement Overview
- Methodology
- Bottom-up forecasting overview
- Bottom-up forecast assumptions
- General sources of data
- Drug-treatment rate assumptions in scleroderma (systemic sclerosis)
- Patient-share assumptions in scleroderma (systemic sclerosis): 2032
- General statements about pricing
- Sources for drug prices
- 2022 exchange rates
- Price per treated day: 2022
- Price per treated day: 2032
- Dosing, days of therapy, and compliance
- Generic erosion
- Generic erosion assumptions
- Biosimilar erosion
- Biosimilar erosion assumptions
- Out-year forecasting
- Forecast therapy prices
- Primary market research
- Appendix
Rafael Widjajahakim, M.S., is an analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. Prior to joining the company, he was a clinical research coordinator at University of Massachusetts Medical School. He received his master of science degree in clinical investigation from Boston University and his bachelor of science degree in biology from Suffolk University.
Naorem Subhadra Devi, M.P.H., Epidemiologist, Epidemiology. Ms. Devi holds a master’s degree in public health with epidemiology as a specialization from Manipal Academy of Higher Education. She also completed a bachelor’s degree in naturopathy and yogic sciences from SVYASA University in Bangalore, India. Her area of interests are lifestyle-related disorders and psychiatry.